Skip to content

Theravance Biopharma TBPH Net Change in Cash

Net Change in Cash at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$33.19M+834%
LQD
Liquidia CorporationLQDA
$32.11M+578%
Royalty Pharma logo
Royalty PharmaRPRX
-$32.3M-120%
United Therapeutics logo
United TherapeuticsUTHR
-$277.4M-237%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
-$39.21M-131%
Precigen logo
PrecigenPGEN
-$22.75M+3.0%

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/E7.8×
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's net change in cash?
Theravance Biopharma (TBPH) reported net change in cash of $120.3M in Q1 2026.
How has Theravance Biopharma's net change in cash changed year-over-year?
Theravance Biopharma's net change in cash increased by 65.2% year-over-year, from $72.82M to $120.3M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.